Hematology-OncologyInnovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma
MedXY Editorial Team
Highlight
- Talquetamab, a bispecific antibody targeting GPRC5D, combined with daratumumab, shows enhanced efficacy in relapsed/refractory multiple myeloma (RRMM).
- The phase 1b TRIMM-2 trial reported overall response rates of up to 82.4% with manageable safety in heavily pretreated patients.
- Median progression-free survival exceeded 20 months, indicating durable disease control.
- The combination leverages daratumumab’s immunomodulatory effects to create an environment conducive to talquetamab activity.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
